CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Melanoma Clinical Trial

Official title:

A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04695977
• Other study ID #: CMP-001-011
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: February 24, 2021
• Est. completion date: July 19, 2024

Study information

• Verified date: January 2024
• Source: Regeneron Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.

The study is divided into two phases: Phase 2 and Phase 3.

The primary objective of Phase 2 of the study is to determine confirmed objective response rate (ORR) for treatment with first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma.

The secondary objective of Phase 2 of the study is to evaluate the safety and tolerability of first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma.

The primary objective of Phase 3 of the study is to evaluate progression-free survival (PFS) for subjects receiving first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy for unresectable or metastatic melanoma.

The secondary objectives of Phase 3 are to:

• To evaluate the safety and tolerability of first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma.

• To evaluate the efficacy of first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma.

Description:

Former Sponsor Checkmate Pharmaceuticals

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: July 19, 2024
• Est. primary completion date: July 19, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects enrolled in the study must meet all of the following inclusion criteria to be eligible:

1. Histologically or cytologically confirmed unresectable Stage III or Stage IV melanoma per AJCC Cancer Staging Manual Eighth Edition.

2. Measurable disease, as defined by RECIST v1.1 and both of the following:

1. At least 1 accessible lesion amenable to repeated IT injection

2. One or more measurable lesions at least 1 cm in diameter that are not intended for CMP-001 injection and can be followed as target lesions per RECIST v1.1

3. Able to provide tissue from a core or excisional biopsy (fine needle aspirate is not sufficient). A newly obtained biopsy (within 90 days before the first dose of study treatment) is preferred, but an archival sample is acceptable if no intervening therapy for melanoma/cancer was received. Note: for tissue sampling details, please refer to the Laboratory Manual.

4. Adequate organ function based on most recent laboratory values within 3 weeks before the first dose of study treatment on Week 1 Day 1 (W1D1):

1. Bone marrow function:

• neutrophil count =1500/mm3

• platelet count = 100 000/mm3

• hemoglobin concentration =9 g/dL

• white blood cells =2000/mm3

2. Liver function:

• total bilirubin =1.5 × the upper limit of normal (ULN) with the following exception: subjects with Gilbert Disease total serum bilirubin =3 × ULN

• aspartate aminotransferase and alanine aminotransferase =3 ×ULN

3. Lactate dehydrogenase =2 × ULN

4. Renal function: estimated (Cockcroft-Gault) or measured creatinine clearance =30 mL/min

5. Coagulation

• International normalized ratio or prothrombin time (PT) = 1.5 × ULN, unless subject is receiving anticoagulant therapy, as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants

• Activated partial thromboplastin time or PTT =1.5 × ULN, unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants

5. Eastern Cooperative Oncology Group Performance Status of 0 to 1 at Screening.

6. Age =18 years at time of consent.

7. Capable of understanding and complying with protocol requirements.

8. Women of childbearing potential must have negative serum pregnancy test prior to dosing at W1D1 and be willing to use an adequate method of contraception from the time of consent until at least 150 days after the last dose of study treatment.

9. Male subjects must be surgically sterile or must agree to use adequate method of contraception from the time of consent until at least 210 days after the last dose of study treatment.

10. Able and willing to provide written informed consent and to follow study instructions.

Subjects unable to provide written informed consent on their own behalf will not be eligible for the study.

Exclusion Criteria:

Subjects presenting with any of the following will not qualify for entry into the study:

1. Uveal, acral, or mucosal melanoma.

2. Received prior systemic treatment for melanoma in the unresectable or metastatic setting. Prior adjuvant therapy is acceptable if the treatment course (of approximately 1 year duration) was completed and there was no recurrence within 6 months of the last dose of adjuvant treatment.

3. Received prior therapy with CMP-001.

4. Requires systemic pharmacologic doses of corticosteroids greater than the equivalent of 10 mg/day prednisone within 30 days before the first dose of study treatment on W1D1.

1. Subjects who are currently receiving steroids at a prednisone-equivalent dose of =10 mg/day do not need to discontinue steroids prior to enrollment.

2. Replacement doses, topical, ophthalmologic, and inhalational steroids are permitted.

5. History of CTCAE v5.0 Grade 4 immune-related AE due to adjuvant CTLA-4 or PD-1 blocking antibody.

6. Not fully recovered from adverse events (to Grade 1 or less [per CTCAE v5.0], with the exception of persistent alopecia, adrenal insufficiency, and hypothyroidism) due to prior treatment.

7. Active pneumonitis, history of pneumonitis that required steroids, or history of interstitial lung disease.

8. Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to poorly controlled hypertension, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association Class II or greater), pericarditis within the previous 6 months, cerebrovascular accident, and implanted or continuous use of a pacemaker or defibrillator.

9. Known history of immunodeficiency.

10. Known additional malignancy that has progressed or required active treatment within the past 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, curatively treated localized prostate cancer with prostate-specific antigen level below 4.0 ng/mL, in situ cervical cancer on biopsy or a squamous intraepithelial lesion on Papanicolaou smear, thyroid cancer (except anaplastic), and adjuvant hormonal therapy for breast cancer >3 years from curative-intent surgical resection.

11. Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment.

12. Untreated, symptomatic, or enlarging central nervous system metastases or carcinomatous meningitis (including leptomeningeal metastases from solid tumors).

13. Prior allogenic tissue/solid organ transplant.

14. Known or suspected active infection with severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2).

15. Active infection requiring systemic therapy.

16. Known or suspected infection with HIV, hepatitis B virus, or hepatitis C virus; testing is not required unless suspected.

17. Received a live/attenuated virus vaccination within 30 days prior to the first dose of study treatment on W1D1.

18. Received blood products (including platelets or red blood cells) or colony stimulating factors (including granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, or recombinant erythropoietin) within 30 days prior to the start of Screening.

19. History of allergy or hypersensitivity to nivolumab and/or any of its excipients.

20. Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator, would make the subject unable to cooperate or participate in the trial.

21. Participation in another clinical study of an investigational anticancer therapy or device within 30 days before the first dose of study treatment on W1D1.

Note: Participation in the follow-up phase (receiving no study treatment) of a prior study is allowed.

22. Requires prohibited treatment (ie, non-protocol specified anticancer pharmacotherapy, surgery, or radiotherapy) for treatment of malignant tumor.

23. Has a life expectancy of less than 3 months and/or has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain) in the opinion of the treating Investigator.

24. Pregnant or breast-feeding or expecting to conceive or donate eggs within the projected duration of the study, from the time of consent until at least 150 days after the last dose of study treatment for women.

Related Conditions & MeSH terms

• Advanced Melanoma
• Melanoma
• Metastatic Melanoma
• Unresectable Melanoma

Intervention

Drug:
• CMP-001
Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
• Nivolumab
Nivolumab 360 mg IV is administered Q3W.

Locations

Country	Name	City	State
United States	University Cancer & Blood Center	Athens	Georgia
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio
United States	Texas Oncology, Sammons Cancer Center	Dallas	Texas
United States	Duke University Cancer Institute	Durham	North Carolina
United States	Hartford Healthcare	Hartford	Connecticut
United States	University of Iowa Hospitals & Clinics	Iowa City	Iowa
United States	Moores Cancer Center at UC San Diego Health	La Jolla	California
United States	University of Arkansas for Medical Sciences	Little Rock	Arkansas
United States	University of California, Los Angeles	Los Angeles	California
United States	USC/Norris Comprehensive Cancer Center	Los Angeles	California
United States	University of Louisville Health Care	Louisville	Kentucky
United States	West Virginia University	Morgantown	West Virginia
United States	Atlantic Health	Morristown	New Jersey
United States	USC Norris Oncology/Hematology-Newport Beach	Newport Beach	California
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	University of Pittsburgh Medical Center / Hillman Cancer Center	Pittsburgh	Pennsylvania
United States	California Cancer Associates for Research & Excellence, Inc.	San Marcos	California
United States	Seattle Cancer Care Alliance	Seattle	Washington
United States	Cleveland Clinic	Weston	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Regeneron Pharmaceuticals	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 2: Determine confirmed objective response with CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma	Objective response rate (ORR) is defined as proportion of subjects with a confirmed objective response of complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as determined by Blinded Independent Central Review (BICR).	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)
Primary	Phase 3: Evaluate progression-free survival for subjects receiving CMP-001 in combination with nivolumab versus nivolumab monotherapy for unresectable or metastatic melanoma	Progression-free survival (PFS) is defined as time from date of randomization to first date of documented progressive disease based on RECIST v1.1 by BICR or death (from any cause, whichever occurs first).	From date of randomization until 30 days after last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 2 & 3: Evaluate the safety & tolerability of CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma defined by AEs, SAEs, & AEs leading to discontinuation or death & severity of AEs.	Defined by adverse events (AEs), serious adverse events (SAEs), & AEs leading to discontinuation or death & severity of AEs as assessed by NCI CTCAE version 5.0.	From time of informed consent until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Overall survival (OS)	The time from the date of randomization to the date of death due to any cause.	From date of randomization until 30 days after last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Confirmed objective response rate (ORR)	The proportion of subjects with a confirmed objective response of CR or PR based on RECIST v1.1 as determined by BICR.	From first dose of drug (Week 1 Day 1) until 30 days after last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Duration of response (DOR)	The time from date of first documented response (CR or PR) to date of documented progressive disease, based on RECIST v1.1 as determined by BICR.	From first dose of drug (Week 1 Day 1) until 30 days after last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Disease control rate (DCR)	The proportion of subjects with confirmed best response of CR or PR, or stable disease lasting at least 4 months, based on RECIST v1.1 as determined by BICR.	From first dose of drug (Week 1 Day 1) until 30 days after last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Treatment response (TR) in non-injected target lesions	The confirmed ORR in non-injected target lesions based on the RECIST v1.1. Treatment response in non-injected lesions based on RECIST v1.1 by investigator assessment (IA).	From first dose of drug (Week 1 Day 1) until 30 days after last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Immune PFS (iPFS)	The time from date of first dose of study drug to date of iCPD by IA or death, whichever occurs first.	From first dose of CMP-001 (Week 1 Day 1) until 30 days after the last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Immune DOR (iDOR)	The time from the date of the first immune response (iCR or iPR) to the date of immune confirmed progressive disease (iCPD) by IA.	From first dose of CMP-001 (Week 1 Day 1) until 30 days after the last CMP-001 injection (until a reason for treatment discontinuation occurs)
Secondary	Phase 3: Immune ORR (iORR)	The proportion of subjects with a best overall response of immune complete response (iCR) or immune partial response (iPR) based on the immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by IA.	From first dose of CMP-001 (Week 1 Day 1) until 30 days after the last CMP-001 injection (until a reason for treatment discontinuation occurs)